Exact Sciences Corporation (EXAS) est une société cotée en bourse dans le Santé secteur, opérant dans le Medical - Diagnostics & Research secteur d'activité. Le siège social de l'entreprise est situé à Madison, WI, United States. Le PDG actuel est Kevin T. Conroy.
EXAS a date d'introduction en bourse 2001-02-01, 6,900 employés à temps plein, cotée sur le NASDAQ Capital Marke, une capitalisation boursière de $20.03B.
Exact Sciences Corporation is a leading provider of cancer screening and diagnostic testing solutions operating across the United States and international markets. The company's flagship product, Cologuard, is a non-invasive stool-based DNA test designed to detect colorectal cancer and pre-cancerous conditions by identifying specific DNA and hemoglobin biomarkers. Beyond screening, Exact Sciences offers a comprehensive portfolio of diagnostic tests including Oncotype DX for gene expression analysis in breast, prostate, and colon cancers, as well as advanced tumor profiling and liquid-based testing solutions for metastatic and refractory cancers. The company maintains strategic partnerships with the Mayo Foundation for Medical Education and Research and Hologic, Inc., while its development pipeline focuses on enhancing existing tests and expanding into blood-based and other fluid diagnostic platforms. Founded in 1995 and headquartered in Madison, Wisconsin, Exact Sciences continues to advance precision oncology and cancer prevention.
